Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo

Novo Nordisk CEO to face off with Bernie Sanders over 1,300% Ozempic markup in U.S.

Novo's Danish CEO Lars Fruergaard Jørgensen will face the U.S. Senate in September to defend Wegovy's and Ozempic's eye-watering prices.

Fortune

ASML, Novo Nordisk, Spotify Boast This Sign Of Stock Market Leadership

Spotify stock, ASML and Novo Nordisk, are in or near buy zones and boast this key signal of stock market leadership.

Investors Business Daily

In China, weight-loss drugs are becoming big business

Chinese pharmaceutical companies are racing to roll out weight-loss drugs amid the popularity of Ozempic.

Al Jazeera

From analysis to the latest developments in health,
read the most diverse news in one place.

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

Investors Business Daily

Novo Helix T50 Carbon Fiber Tripod Kit review

This feature-packed travel tripod packs down unfeasibly small, yet extends reasonably tall

Digital Camera World

Danish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bn

Novo Nordisk, which is now Europe’s most valuable company, also reports strong sales of diabetes drug Ozempic

The Guardian - UK

Novo Nordisk Dips After Wegovy Sales Double, But Miss Analysts' Forecast

Novo Nordisk stock dipped Thursday after sales of weight-loss drug, Wegovy, nearly doubled, but missed even more bullish expectations.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Weight Loss Leader Novo Nordisk Hits Buy Trigger In Stock Market Rebound

Novo Nordisk stock: The weight-loss drug leader hit a buy point in the recent stock market rebound and is one of the best stocks to watch.

Investors Business Daily

Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit

Metabolic health is all the rage, helped by the advent of weight-loss drugs and continuous glucose monitors. Can they change disease forever?

Investors Business Daily

IBD Stock Of The Day Novo Nordisk: Why A Pullback Is Bullish For The Weight-Loss Kingpin

The company leads the weight-loss drugs market with its blockbuster, Wegovy. But next-generation drugs are coming.

Investors Business Daily

Stock Market Rally Hits Fresh Highs As Nvidia, Novo Nordisk, Bitcoin Soar: Weekly Review

The Nasdaq and S&P 500 hit fresh all-time highs, with Nvidia and bitcoin continuing to surge.

Investors Business Daily

U.S. Stocks Aren't The Only Game In Town: Arm, Novo Please Investors

Arm Stock and Novo Nordisk stock topped this screen of leading global growth stocks. One of them is near a buy point.

Investors Business Daily

Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News

DaVita stock launched Tuesday after Novo Nordisk unveiled the results of its weight-loss drug in kidney disease patients.

Investors Business Daily

How The Red-Hot Obesity Space Could Help Eli Lilly Join The 1,000 Club

Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Barchart

Europe's Most Valuable Stock Is a Must-Own Near 52-Week Highs

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

Barchart

Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a Better Buy for 2024?

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

Investors Business Daily

Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record

Amgen stock slumped Monday — as Eli Lilly stock hit a record high — after the company unveiled preclinical results for its weight-loss drug.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novo Nordisk To Up Production Capacity As Parent Buys Catalent

Shares in Novo Nordisk rose after its parent, Novo Holdings, said it has agreed to by contract drug manufacturer Catalent for $11.5 billion in cash.

Investors Business Daily

Novo Stock Surges Out Of A Buy Zone On Ozempic's Commanding Sales Beat

Novo Nordisk stock popped Wednesday after its biggest moneymaker, a diabetes drug called Ozempic, put up a commanding fourth-quarter beat.

Investors Business Daily

Wall Street Raises The Bar For These Four Stocks In 2024

Nvidia is one of four stocks with rising profit estimates for 2024. Others are MercadoLibre, Deckers Outdoor and Novo Nordisk.

Investors Business Daily

Novo Nordisk, IBD Stock Of The Day, Flashes Buy Signal Amid The Weight-Loss Craze

Novo Nordisk stock is Friday's IBD Stock Of The Day. Shares are in a buy zone after the firm inked deals in the weight-loss drugs space.

Investors Business Daily

Stock Market Skids To Start 2024 As Tesla, Apple Stumble, Mobileye Crashes: Weekly Review

The S&P 500 snapped a nine-week win streak, but tried to find support. Tesla, Apple and Mobileye were key losers.

Investors Business Daily

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Biotech stocks are heating up as multibillion-dollar deals pile up and new modalities like CRISPR gene-editing hit prime time.

Investors Business Daily

Novo Nordisk, The Weight-Loss Kingpin, Breaks Out After Inking Two New Deals In Obesity

Novo Nordisk inked a pair of deals Thursday to bolster its weight-loss drugs franchise, and sent shares of Omega into the stratosphere.

1 2 3 4 5

People

Lars Fruergaard Jørgensen

10 stories

Margaret Kaczor Andrew

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.